Data gathered: May 29
AI Stock Analysis - Viking Therapeutics (VKTX)
Analysis generated December 30, 2024. Powered by Chat GPT.
Viking Therapeutics is a biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. Their product pipeline includes several investigational drugs targeting various therapeutic areas such as non-alcoholic steatohepatitis (NASH) and various other conditions. The company places a strong emphasis on innovation and research, aiming to deliver transformative therapies to patients in need.
Stock Alerts - Viking Therapeutics (VKTX)
 |
Viking Therapeutics | May 6 Price is down by -7% in the last 24h. |
|
Viking Therapeutics | April 29 Price is up by 10.2% in the last 24h. |
|
Viking Therapeutics | April 22 Price is up by 7.4% in the last 24h. |
|
Viking Therapeutics | April 17 Price is down by -8.1% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Viking Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 95 | Sign up | Sign up | Sign up |
| Webpage traffic | 29,000 | Sign up | Sign up | Sign up |
| Employee Rating | N/A | Sign up | Sign up | Sign up |
| Google Trends | 11 | Sign up | Sign up | Sign up |
| Patents | 15 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 223 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 32,703 | Sign up | Sign up | Sign up |
| Twitter Followers | 4,317 | Sign up | Sign up | Sign up |
| Twitter Mentions | 252 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 41 | Sign up | Sign up | Sign up |
About Viking Therapeutics
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.
| Price | $27.13 |
| Target Price | Sign up |
| Volume | 2,510,000 |
| Market Cap | $3.05B |
| Year Range | $19.98 - $78.03 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Novo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock Has More Upside?May 27 - Yahoo |
Viking Therapeutics: Buy It For The Future And Ignore The NoiseMay 26 - SeekingAlpha |
|
 |
Better Weight Loss Stock: Amgen or Viking Therapeutics?May 22 - Biztoc.com |
 |
Viking Therapeutics: Weight-Loss Story Remains IntactMay 21 - SeekingAlpha |
 |
Viking Therapeutics: A High Potential Biotech Play With Manageable RisksMay 19 - SeekingAlpha |
 |
Viking Therapeutics: Near-Term Catalysts And Competitor ReadoutsMay 19 - SeekingAlpha |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '25 | 0 | 0 | 0 | -46M | -55M | -0.410 |
| Q4 '24 | 0 | 0 | 0 | -35M | -46M | -0.320 |
| Q3 '24 | 0 | 87,000 | -87,000 | -25M | -37M | -0.220 |
| Q2 '24 | 0 | 75,000 | -75,000 | -22M | -34M | -0.200 |
| Q1 '24 | 0 | 74,000 | -74,000 | -27M | -34M | -0.260 |
Insider Transactions View All
| Rouan Sarah Kathryn filed to buy 1,240 shares at $24.1. April 2 '25 |
| Rouan Sarah Kathryn filed to buy 1,240 shares at $24.1. April 8 '25 |
| ZANTE GREG filed to sell 165,259 shares at $43.3. January 6 '25 |
| Mancini Marianna filed to sell 374,134 shares at $43.3. January 6 '25 |
| ZANTE GREG filed to sell 169,959 shares at $42.7. January 6 '25 |
Similar companies
Read more about Viking Therapeutics (VKTX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Viking Therapeutics?
The Market Cap of Viking Therapeutics is $3.05B.
What is the current stock price of Viking Therapeutics?
Currently, the price of one share of Viking Therapeutics stock is $27.13.
How can I analyze the VKTX stock price chart for investment decisions?
The VKTX stock price chart above provides a comprehensive visual representation of Viking Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Viking Therapeutics shares. Our platform offers an up-to-date VKTX stock price chart, along with technical data analysis and alternative data insights.
Does VKTX offer dividends to its shareholders?
As of our latest update, Viking Therapeutics (VKTX) does not offer dividends to its shareholders. Investors interested in Viking Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Viking Therapeutics?
Some of the similar stocks of Viking Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.